2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5337 CHOP plus CD20 monoclonal antibody and lenalidomide markedly reduces POD24 in young patients with high-risk follicular lymphoma: A prospective single-arm study

Rui Lv, MD, Tingyu of Wang2, Wenjie Xiong3, Yuting Yan, MD4, Ying Yu5, Wei LIU6, Wenyang Huang, MD7, Weiwei Sui8, Yan Xu, MD9, Dehui Zou, MD10, Gang An, MD11, Lu-Gui Qiu, PhD12, Shuhua Yi, DO13
1 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
7 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
8 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
9 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
10 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
11 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin, China, Tianjin, China
12 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
13 Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Background: Disease progression within 24 months (POD24) occurs in ~30% of follicular lymphoma (FL) patients and identifies a poor-prognosis subgroup that partially overlaps with high-risk FLIPI, FLIPI-2, and PRIMA-PI categories. For young patients (<65 years) with these high-risk features, effective strategies to lower POD24 incidence remain an unmet need.

 

Methods: This prospective single-arm study (IIT2021030-EC-1) enrolled 97 treatment-naïve patients aged <65 years with stage III–IV FL meeting GELF criteria and at least one high-risk indicator. High-risk features were stringently defined to capture the most aggressive biology: high-risk FLIPI, FLIPI-2, or PRIMA-PI; lymphocyte count >5×10?/L; SUVmax >5× hepatic pool; grade 3A histology; or TP53 aberrations. All received CHOP + rituximab (or obinutuzumab) + lenalidomide 25 mg D1–10. Primary endpoint: POD24 rate.

 

Results: Among 97 patients (median age 48 years, ECOG 0–1), the prevalence of high-risk features was exceptionally high: bone marrow involvement 83.5%, bulky disease (>6 cm) 54.6%. Overall, 67.0% were classified as high-risk by FLIPI, FLIPI-2, or PRIMA-PI. Among the remaining 32 patients, the proportions with highly aggressive features were 37.5% for lymphocyte count >5×10?/L, 37.5% for SUVmax >5× hepatic, 40.6% for grade 3A, and 6.3% for TP53 abnormalities. Notably, 60.8% of patients exhibited two or more high-risk features simultaneously. At median follow-up of 31(25-57) months, 3-year PFS was 78.5%, 3-year OS 95.9%, and CR rate 70.1%. The overall POD24 rate was only 12.5%, and even in the multi-high-risk subgroup it was 14.2%—substantially lower than historical benchmarks (34.1% for FLIPI-high, 22.5% for FLIPI-2-high, 21.9% for PRIMA-PI-high)1. Grade ≥3 leukopenia and neutropenia occurred in 34.0% and 35.1%, respectively; febrile neutropenia 3.1%. Grade ≥3 pulmonary infections occurred in 10.3%; cardiac/vascular events were rare.

 

Conclusions: In young, high-risk FL patients with aggressive clinicobiological features, CHOP + CD20 mAb + lenalidomide demonstrated potent activity, yielding a POD24 rate far below historical high-risk controls. The safety profile was predictable and manageable. This regimen represents a promising frontline option for this underserved population and warrants further validation in randomized trials.

 

Keywords: High-risk follicular lymphoma; POD24; first-line chemoimmunotherapy

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Rodriguez-Sevilla J J, Fernández-Rodríguez C, Bento L, et al. Blood Adv 2023;7(8):1606-1614.
Rui Lv, MD: No relevant conflicts of interest to declare.